Given that the genetic profile for driver mutations of cancer-related oncogenes and immune checkpoint molecules of PD-L1 with tumor mutation burden and microsatellite instability might stratify clinical outcomes in patients with the same primary cancers, we need a predictive prognostic biomarker for reflecting the clinical prognosis of patients with BM. Here, CD274 is linked to cancer.